共 50 条
- [11] A Phase 1b, Multicenter, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Tegoprubart (AT-1501) in Patients Undergoing Kidney TransplantJOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 967 - 967Tchervenkov, JeanCoates, Patrick T.Kadatz, Matthew J.Bornstein, Jeffrey D.Gill, John S.
- [12] Phase 1b study of crizotinib in combination with pembrolizumab in patients (pts) with untreated ALK-positive (+) advanced non-small cell lung cancer (NSCLC)ANNALS OF ONCOLOGY, 2016, 27Vizcarrondo, F. R.Patel, S. P.Pennell, N. A.Pakkala, S.West, H.Kratzke, R.Tarazi, J.Wilner, K.Polli, A.Tan, W.Liu, Y.Valota, O.Piperdi, B.Reckamp, K. L.
- [14] Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialLANCET, 2017, 390 (10089): : 29 - 39Hida, ToyoakiNokihara, HiroshiKondo, MasashiKim, Young HakAzuma, KoichiSeto, TakashiTakiguchi, YuichiNishio, MakotoYoshioka, HiroshigeImamura, FumioHotta, KatsuyukiWatanabe, SatoshiGoto, KoichiSatouchi, MiyakoKozuki, ToshiyukiShukuya, TakehitoNakagawa, KazuhikoMitsudomi, TetsuyaYamamoto, NobuyukiAsakawa, TakashiAsabe, RyoichiTanaka, TomohiroTamura, Tomohide
- [15] Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trialSIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)Yang, YunpengMin, JieYang, NongYu, QitaoCheng, YingZhao, YanqiuLi, ManxiangChen, HongRen, ShouanZhou, JianyingZhuang, WuQin, XintianCao, LejieYu, YanZhang, JianHe, JianxingFeng, JifengYu, HaoZhang, LiFang, Wenfeng
- [16] A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MSNeurotherapeutics, 2023, 20 : 1263 - 1274Scott D. NewsomeFan TianThomas ShoemakerKathryn C. FitzgeraldSandra D. CassardJulie FiolSarah SnoopsDavid S. CooperJennifer S. R. MammenPavan BhargavaEllen M. MowryPeter A. Calabresi
- [17] Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trialSignal Transduction and Targeted Therapy, 8Yunpeng YangJie MinNong YangQitao YuYing ChengYanqiu ZhaoManxiang LiHong ChenShou’an RenJianying ZhouWu ZhuangXintian QinLejie CaoYan YuJian ZhangJianxing HeJifeng FengHao YuLi ZhangWenfeng Fang
- [18] A Phase 1b, Open-Label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals with MSNEUROTHERAPEUTICS, 2023, 20 (05) : 1263 - 1274Newsome, Scott D.Tian, FanShoemaker, ThomasFitzgerald, Kathryn C.Cassard, Sandra D.Fiol, JulieSnoops, SarahCooper, David S.Mammen, Jennifer S. R.Bhargava, PavanMowry, Ellen M.Calabresi, Peter A.
- [19] Safety and efficacy profile of crizotinib in the French Temporary Authorization for Use (ATU) of crizotinib in patients (pts) with ALK-positive (+) advanced NSCLCEUROPEAN JOURNAL OF CANCER, 2013, 49 : S799 - S799Perol, M.Cadranel, J.Planchard, D.Dansin, E.Bigay-Game, L.Audigier-Valettee, C.Scherpereel, A.Buturuga, A.Moro-Sibilot, D.Besse, B.
- [20] Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myelomaLEUKEMIA RESEARCH, 2019, 83Hari, ParameswaranPaba-Prada, Claudia E.Voorhees, Peter M.Frye, JohnChang, Yu-LinMoreau, PhilippeZonder, JeffreyBoccia, RalphShain, Kenneth H.